| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 02/13/2002 | EP1179065A2 Full-length molecules expressed in human tissues |
| 02/13/2002 | EP1179063A2 Genes expressed in hippocampus |
| 02/13/2002 | EP1179002A1 Methods using mechanisms of action of aroa |
| 02/13/2002 | EP1178983A1 Indole-type derivatives as inhibitors of p38 kinase |
| 02/13/2002 | EP1178982A1 Heterocyclic substituted aminoazacycles useful as central nervous system agents |
| 02/13/2002 | EP1178977A1 Ion channel modulating agents |
| 02/13/2002 | EP1178970A1 Substituted polycyclic aryl and heteroaryl pyrymidinones useful as anticoagulants |
| 02/13/2002 | EP1178964A1 Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade |
| 02/13/2002 | EP1178958A2 N-cyanomethyl amides as protease inhibitors |
| 02/13/2002 | EP1178832A1 Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics |
| 02/13/2002 | EP1178831A1 Combined method of treatment comprising an aromatase inhibitor and a further biologically active compound |
| 02/13/2002 | EP1178828A1 Death domain containing receptor 4 |
| 02/13/2002 | EP1178821A1 Use of heparin-binding antagonists in the inhibition of bradykinin release |
| 02/13/2002 | EP1178820A1 Methods of modulating fabh activity |
| 02/13/2002 | EP1178819A2 Glutathione reductase for therapy and prophylaxis of aids |
| 02/13/2002 | EP1178817A2 Molecular interactions in haematopoietic cells |
| 02/13/2002 | EP1178815A1 Death domain containing receptors |
| 02/13/2002 | EP1178814A1 A method of identifying therapeutic compounds for a treatment of hepatic disorders |
| 02/13/2002 | EP1178812A2 Conditioned cell culture medium compositions and methods of use |
| 02/13/2002 | EP1178811A1 Electrolyte gels for maintaining hydration and rehydration |
| 02/13/2002 | EP1178803A2 Opioid antagonists containing compositions for enhancing analgesic potency of tramadol and attenuating its adverse side effects |
| 02/13/2002 | EP1178799A1 Microgranules insoluble in gastric fluid, method for obtaining same and pharmaceutical preparations |
| 02/13/2002 | EP1178797A1 Inhibitors of impdh enzyme |
| 02/13/2002 | EP1178795A1 Dfmo and celecoxib in combination for cancer chemoprevention and therapy |
| 02/13/2002 | EP1178791A2 The use of a protein tyrosine kinase pathway inhibitor in the treatment of ocular disorders |
| 02/13/2002 | EP1178784A1 New pharmaceutical combinations for nos inhibitors |
| 02/13/2002 | EP1178783A1 Device and method for increasing the transdermal permeation of medicaments |
| 02/13/2002 | EP1178780A1 Multiparticulate controlled release selective serotonin reuptake inhibitor formulations |
| 02/13/2002 | EP1178776A1 Methods of regulating the condition of mammalian keratinous tissue |
| 02/13/2002 | EP1178736A1 A composition containing carvacrol and thymol for use as a bactericide |
| 02/13/2002 | EP1178727A1 A therapeutic mixture useful in inhibiting lesion formation after vascular injury |
| 02/13/2002 | EP0861081B1 Use of epinastine in the treatment of pain |
| 02/13/2002 | CN1335887A Angiocidin: A Cys-Ser-Val-Thr-Cys-Gly specific tumor cell adhesion receptor |
| 02/13/2002 | CN1335835A Arylpiperidine and aryl-1,2,5,6-tetrahydropyridine urea derivatives having 5HT1A receptor activity |
| 02/13/2002 | CN1335765A Polyol/oil suspensions for the sustained release of proteins |
| 02/13/2002 | CN1335764A Substrate composition and method of use for sequestration of skin irritants |
| 02/13/2002 | CN1335757A Hemostatic polymer useful for rapid blood coagulation and hemostasis |
| 02/13/2002 | CN1335749A Method and compositions for treatment of cell proliferative disorders |
| 02/12/2002 | US6346608 MecB |
| 02/12/2002 | US6346607 A protein that induces apoptosis or binds cytochrome c; diagnosis and therapy for multiple sclerosis, parkinson's and alzheimer's diseases, cardiovascular diseases, strokes, toxin induced liver disease, cancer, lupus and herpes virus |
| 02/12/2002 | US6346543 Administering baccatin derivative as anticarcinogenic agent |
| 02/12/2002 | US6346528 Side effect reduction compared to olanzapine; capsules or tablets; psychological, gastrointestinal and bipolar disorders; anxiolytic agents, antidepressants |
| 02/12/2002 | US6346519 Method and composition for treating arthritis |
| 02/12/2002 | US6346517 Synergy between low molecular weight heparin and platelet aggregation inhibitors, providing a combination therapy for the prevention and treatment of various thromboembolic disorders |
| 02/12/2002 | US6346516 Drug delivery of (quaternary) amine salt and macromolecule; gene therapy |
| 02/12/2002 | US6346409 Tryptophenyl tRNA synthetase from Streptococcus pneumoniae |
| 02/12/2002 | US6346392 Amino acid sequence from streptococcus; drug screening of bactericides and bacteriostats |
| 02/12/2002 | US6346391 Treating infection by administering drug to which the microorganism is resistant and an inhibitor of an acrab-like efflux pump |
| 02/12/2002 | US6346275 Drugs for immunology residues of corallinaceae, seaweed derivatives |
| 02/12/2002 | US6346247 Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies |
| 02/12/2002 | US6346242 Compounds and compositions for delivering active agents |
| 02/12/2002 | US6346233 Composition for treating cancer via liposomal aerosol formulation containing taxol |
| 02/12/2002 | US6346098 Methods and kits for locally administering an active agent to an interstitial space of a host |
| 02/12/2002 | CA2303685C Fluorocarbon aerosol medicaments |
| 02/12/2002 | CA2259152C Adenovirus e4 proteins for inducing cell death |
| 02/09/2002 | CA2354051A1 Ribosome structure and protein synthesis inhibitors |
| 02/07/2002 | WO2002010766A2 Assay method, peptides and reagent kits for testing mrp-specific inhibitors |
| 02/07/2002 | WO2002010743A1 Improved anti-viral and anti-tumor chemotherapy by administration of erythropoeitin |
| 02/07/2002 | WO2002010403A2 Regulation of human phosphatidylinositol-specific phospholipase c-like enzyme |
| 02/07/2002 | WO2002010402A2 Isolation of drosophila and human polynucleotides encoding par-1 kinase, polypeptides encoded by the polynucleotides and methods utilizing the polynucleotides and polypeptides |
| 02/07/2002 | WO2002010393A2 Isolated nucleic acid molecules which encode t cell inducible factors, or interleukin-21, the proteins encoded, and uses thereof |
| 02/07/2002 | WO2002010387A2 G-protein coupled receptors |
| 02/07/2002 | WO2002010382A2 Trp8, trp9 and trp10, markers for cancer |
| 02/07/2002 | WO2002010363A2 Protein phosphatases |
| 02/07/2002 | WO2002010339A2 Gene expression profile for kshv infection and methods for treating same |
| 02/07/2002 | WO2002010214A2 Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
| 02/07/2002 | WO2002010192A2 Somatostatin analogues |
| 02/07/2002 | WO2002010169A1 Piperazine derivatives |
| 02/07/2002 | WO2002010162A1 N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl] carboxamide inhibitors of cyclin dependent kinases |
| 02/07/2002 | WO2002010159A1 Lactam inhibitors of factor xa which are useful for the treatment of thrombosis |
| 02/07/2002 | WO2002010146A1 Carboxamide compounds and their use as antagonists of a human 11cby receptor |
| 02/07/2002 | WO2002010141A1 Imidazole derivatives |
| 02/07/2002 | WO2002009815A2 New pharmaceutical composition |
| 02/07/2002 | WO2002009814A2 New use of lipase inhibitors |
| 02/07/2002 | WO2002009787A1 Microparticulate biomaterial composition for medical use |
| 02/07/2002 | WO2002009762A2 Non-peptide ccr1 receptor antagonists in combination with cyclosporin a for the treatment of heart transplant rejection |
| 02/07/2002 | WO2002009761A2 Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure |
| 02/07/2002 | WO2002009760A2 Epoxy-steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure |
| 02/07/2002 | WO2002009759A2 Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders |
| 02/07/2002 | WO2002009758A2 Inhibitors of cellular efflux pumps of microbes |
| 02/07/2002 | WO2002009755A2 Apo-2l receptor agonist and cpt-11 synergism |
| 02/07/2002 | WO2002009742A1 Method for treating a pancreatic disorder with a neurotoxin |
| 02/07/2002 | WO2002009731A1 Use of co for treating inflammation of upper airways or bronchi |
| 02/07/2002 | WO2002009727A1 Compositions and methods for improving cardiovascular function |
| 02/07/2002 | WO2002009716A2 Use of an aldehyde 5-oxo-1,2,4-triazine hydrazide for the treatment of cancer |
| 02/07/2002 | WO2002009715A2 Use of an arylaldehyde 5-oxo-1, 2, 4-triazine hydrazide for the treatment of cancer |
| 02/07/2002 | WO2002009714A1 Compositions and methods for the treatment of anorectal disorders |
| 02/07/2002 | WO2002009702A2 Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure |
| 02/07/2002 | WO2002009701A1 Use of selective adenosine a1 receptor agonists, antagonists and allosteric enhancers to manipulate angiogenesis |
| 02/07/2002 | WO2002009700A1 Cancer treatment by combination therapy |
| 02/07/2002 | WO2002009699A2 Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract |
| 02/07/2002 | WO2002009696A1 Methods for treating cell proliferative disorders and viral infections |
| 02/07/2002 | WO2002009694A1 Anticonvulsant derivatives useful for the treatment of depression |
| 02/07/2002 | WO2002009690A2 Pharmaceutical composition comprising a photochemotherapeutic agent and a mucoadhesive agent |
| 02/07/2002 | WO2002009689A1 Method for reducing exacerbations associated with copd |
| 02/07/2002 | WO2002009683A2 Aldosterone blocker therapy to prevent or treat inflammation-related disorders |
| 02/07/2002 | WO2002009682A2 Use of fibrates for the preparation of a medicament useful in the treatment of congestive heart failure |
| 02/07/2002 | WO2002009677A2 Method to treat infectious diseases and/or to enhance antimicrobial efficacy of drugs |
| 02/07/2002 | WO2002009667A2 Dispersions for formulating slightly or poorly soluble active ingredients |
| 02/07/2002 | WO2002009643A2 Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis |